Evogen

Evogen launched a clinical trial to further validate its proteomic test for distinguishing between epileptic seizures and psychogenic non-epileptic seizures.

Evogen's protein biomarker-based test is designed to stratify actively seizing patients from those who have not experienced a recent seizure.

The company is developing an epilepsy test based on inflammatory proteins in patient blood that is intended for ruling out patients with seizure-like symptoms.